Asia Pacific Wound Care Biologics Market Size (2024 - 2029)

Asia Pacific Wound Care Biologics Market Analysis

The Asia Pacific Wound Care Biologics Market size is estimated at USD 431.12 million in 2024, and is expected to reach USD 595.57 million by 2029, growing at a CAGR of 6.68% during the forecast period (2024-2029).

The factors driving the growth of the wound biologics market are the rising chronic wound prevalence, including pressure ulcers and diabetic foot ulcers, increasing road accidents, and the presence of several players and their strategic initiatives, such as collaborations, partnerships, and mergers and acquisitions. 

The prevalence of traffic accidents and the resulting injuries influence the Asia-Pacific wound care biologics market. According to the article published by the Nippon Communications Foundation in January 2024, traffic accidents increased by 7,072 in Japan to 307 thousand incidents in 2023. Moreover, the number of people injured in these accidents rose to 365 thousand, marking an increase of 8,426 individuals. As the burden of traffic-related injuries continues to rise, there is a growing imperative to invest in advanced biologic therapies and innovative treatment modalities to address the complex needs of wound care effectively.

The rising incidence of chronic wounds and advancements in biotechnology drive the market's growth. For instance, in May 2023, an article published by the National Institute of Health reported that the proportion of patients requiring hospitalization due to chronic wounds was 1.7% in China, mainly among people aged 40-60 years (31%) and 60-80 years (38%). The leading causes of chronic wounds are diabetes, traumatic and pressure injuries, etc. Thus, a rise in chronic wounds would drive the demand for the wound care biologics market in the country.

Government initiatives in wound care are poised to significantly boost market growth. In March 2024, Wounds Australia and the Australian College of Nursing (ACN) secured grants from the Commonwealth of Australia. These grants aim to support innovative projects that enhance the comprehension of wound care, targeting both healthcare professionals and the wider community. Notably, Wounds Australia is set to receive a substantial AUD 2 million (USD 1.44 million) to spearhead a nationwide campaign focused on educating and raising awareness about chronic wound prevention and treatment. Increasing awareness of the treatment is likely to enhance the requirement for biologics wound care, resulting in market growth over the forecast period.

Hence, the growing incidence rate of road accidents, coupled with growing chronic wounds and awareness programs, will likely accelerate the requirement for biologics wound care, resulting in market growth. However, the regulatory challenges and high costs associated with biologics are expected to restrict the demand for wound care biologics.

Asia Pacific Wound Care Biologics Industry Segmentation

As per the report, wound care biologics refer to products that control and heal infections. Wound healing is a complex process involving inflammation, accumulation of tissue, deposition of collagen, and formation of epithelial cell layers.  

The Asia-Pacific wound care biologics market is segmented by product, wound type, end user, and country. By product, the market is segmented into biologic skin substitutes and topical agents. By wound type, the market is segmented into ulcers, surgical and traumatic wounds, and burns. By ulcers, the market is segmented into diabetic foot ulcers, venous ulcers, pressure ulcers, and other ulcers. By end user, the market is segmented into hospitals/clinics, ambulatory surgical centers, and other end users. By country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The report offers market sizes and forecasts for all the above segments in terms of value (USD).